Evaluation Of Relys®: A Novel Modulator Of Ocular Surface In Routine Clinical Practice
Published 2024 - 42nd Congress of the ESCRS
Reference: PO935 | Type: Poster | DOI: 10.82333/p1v3-gh82
Authors: Raquel Monge Carmona* 1 , Álvaro Moreno Guerrero 2 , Carmen Garrido Marquez 2 , Ana Flores Cano 2 , Manuel Caro Magdaleno 3
1Ophthalmology,Virgen Macarena University Hospital,Seville,Spain;Area of Optics,Seville University,Seville,Spain, 2Ophthalmology,Virgen Macarena University Hospital,Seville,Spain, 3Ophthalmology,Virgen Macarena University Hospital,Seville,Spain;Surgery Department,Seville University,Seville,Spain
Purpose
The aim of this study was to comprehensively evaluate the effectiveness of Relys®, a novel modulator of the ocular surface, in patients presenting with various ocular surface conditions during routine clinical examinations. These conditions encompassed dry eye syndrome, blepharitis, pre and post ocular surgery conditions, and other ocular surface disorders. Modulators of the ocular surface, such as Relys®, are polymers with scientifically demonstrated ability to interact with the ocular surface and influence it, promoting homeostasis and ultimately modulating the inflammatory process.
Setting
The study was conducted across multiple ophthalmology clinics as part of routine clinical practice. Patients underwent evaluations utilizing standard diagnostic equipment, including the Keratograph 5M (K5M, Oculus, Wetzlar, Germany), enabling detailed analysis of the ocular surface.
Methods
Patients undergoing routine clinical examinations were included in the study. Prior to and following the application of Relys®, objective measurements were obtained utilizing the Keratograph 5M. Parameters such as tear film stability, meibomian gland function, ocular surface inflammation, hyperemia, tear film break-up time, and ocular surface evaluation with fluorescein staining were assessed. Images illustrating the ocular surface before and after treatment will be presented.
Results
Preliminary observations following the administration of Relys® will be presented. These observations may include changes in ocular surface parameters such as tear film stability, meibomian gland function, ocular discomfort, inflammation, hyperemia, and tear film break-up time. Further analysis is necessary to determine the significance of these observations conclusively.
Conclusions
Relys® shows potential as a therapeutic option for modulating the ocular surface in patients with various ocular surface conditions. The results obtained in this study are ongoing and will continue to be analyzed over several months of follow-up to obtain more conclusive results. Given the lack of existing literature on this specific tear, our findings propose a novel and intriguing approach in ocular surface modulation.